MediciNova is set to receive funding from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) for a Phase llb clinical trial to examine MN-166 (ibudilast) as a potential treatment to decrease alcohol consumption in patients with alcohol use disorder (AUD).

NIAAA is a unit of the US National Institutes of Health (NIH). The funding has been awarded to the trial’s principal investigator Dr Lara Ray.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Ray said: “If MN-166 (ibudilast) is able to reduce drinking compared to placebo in this new study, it will set the stage for a pivotal multi-site clinical trial leading to potential FDA approval of a novel AUD treatment.”

The Phase llb trial is a randomised, double-blind, placebo-controlled, outpatient study which will enrol up to 132 treatment-seeking men and women with moderate or severe AUD.

As part of the trial, the patients will receive 50mg of MN-166 (ibudilast) or placebo twice a day for 12 weeks.

“If MN-166 (ibudilast) is able to reduce drinking compared to placebo in this new study, it will set the stage for a pivotal multi-site clinical trial leading to potential FDA approval of a novel AUD treatment.”

The patients will also complete NIAAA’s web-based programme Take Control during the trial.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial’s primary endpoint is to check whether MN-166 (ibudilast) will decrease the percentage of heavy drinking days, defined as more than five drinks for men and more than four drinks for women, compared to placebo throughout the 12-week long trial.

Its secondary endpoints are to check the efficacy of MN-166 (ibudilast) against various parameters, including the number of drinks consumed per day, the percentage of days abstinent, as well as measures of alcohol craving and negative mood, among others.

The trial’s exploratory endpoints comprise whether the effects of MN-166 (ibudilast) on the primary and secondary endpoints are moderated by depressive symptomatology and whether MN-166 (ibudilast) reduces neuroinflammation during the trial.